Market Place
Sourcing Support
Positive Ph 3 Results for Gazyva Show Superior to Std Therapy alone
26 Sep 2024 //
BUSSINESSWIRE
AstraZeneca trumpets new Calquence combos in chronic lymphocytic leukaemia
30 Jul 2024 //
PRESS RELEASE
US FDA approves expanded use of BeiGene`s blood cancer drug
08 Mar 2024 //
REUTERS
Nektar and Collaborators Present Data on NKTR-255 in Presentation
11 Dec 2023 //
PR NEWSWIRE
Roche withdraws EMA expansion application for cancer medicine Gazyvaro
21 Jul 2023 //
ENDPTS
Long-Term ROSEWOOD Data Confirm Efficacy of Zanubrutinib Plus
27 Jun 2023 //
ONCOLIVE
Venetoclax/Atezolizumab/Obinutuzumab Elicits Durable Responses in Richter
23 Jun 2023 //
ONCOLIVE
Venetoclax Plus Obinutuzumab Demonstrates Durable Survival Benefit
22 Jun 2023 //
PRESS RELAESE
Ibrutinib, Obinutuzumab, Venetoclax Triplet Elicits Clinical Benefit in MCL
19 Jun 2023 //
ONCLIVE
Chugai Pharma’s Gazyva gets Japanese MHLW approval for an additional indication
24 Dec 2022 //
PHARMABIZ
Genentech`s Gazyva (obinutuzumab) Receives BLA Approval in the U.S.
27 Jul 2022 //
FDA
Genentech`s Gazyva (obinutuzumab) Receives Supplemental Approval in U.S.
12 Jul 2022 //
FDA
J&J gets EMA backing for Imbruvica-venetoclax combination
29 Jun 2022 //
FIERCEPHARMA
CALQUENCE Plus Obinutuzumab Demonstrated Sustained Survival Benefit in CLL
04 Jun 2022 //
BUSINESSWIRE
SMC accepts chemotherapy-free VENCLYXTO for leukaemia treatment
10 May 2022 //
PHARMAFILE
Genentech`s Biologic Gazyva (Obinutuzumab) Receives Approval in the U.S.
14 Feb 2022 //
FDA
TG Therapeutics Falls 30% As CEO Discloses Partial Clinical Hold
28 Jan 2022 //
YAHOO FINANCE
Roche’s Gazyvaro shorter 90-minute infusion time approved in Europe
13 Oct 2021 //
GLOBENEWSWIRE
First-Line Ibrutinib/Venetoclax Better Than Chlorambucil/Obinutuzumab
18 Jun 2021 //
CANCERTHERAPYADVISOR
Janssen CLL treatment combination sees success in trials
15 Jun 2021 //
PHARMAFILE
Imbruvica/Venclyxto tops Gazyva plus chemo in first-line CLL/SLL
14 Jun 2021 //
PHARMATIMES
IMBRUVICA Plus VENCLEXTA/VENCLYXTO (venetoclax) Combination Positive Results
14 Jun 2021 //
PRESS RELEASE
CBMG` Novel CD19/CD20 Bi-specific CAR-T Cell Product Shows Promising Results
10 Jun 2021 //
PRNEWSWIRE
CBMG` Novel Anti-CD20 CAR-T Cell Therapy Shows Promising Safety and Efficacy
10 Jun 2021 //
PRNEWSWIRE
Genentech Reports Data at EHA2021 Reinforcing Efficacy of Venclexta Combinations
10 Jun 2021 //
BUSINESSWIRE
NICE recommends new chemo-free chronic lymphocytic leukaemia treatment
13 Nov 2020 //
EUROPEANPHARMACEUTICALREVIEW
EHA25Virtual: Advances in Treatment of High Risk Chronic Lymphocytic Leukemia
12 Jun 2020 //
PRNEWSWIRE
NICE backs Roche’s Gazyvaro, Pfizer’s Lorviqua in new guidance
13 May 2020 //
PMLIVE
AbbVie Receives Health Canada Approval for the Combination of VENCLEXTA®
05 May 2020 //
NEWSWIRE
Genentech`s Gazyva (rituximab) Receives Supplimental Approval In U.S
31 Mar 2020 //
FDA
Roche steers Gazyva into a new PhIII program after combo shows promise
11 Nov 2019 //
PRESS RELEASE
FDA Breakthrough granted for Roche’s Gazyva
19 Sep 2019 //
PHARMATIMES
Roche bid to recycle Gazyva for lupus nephritis wins FDA breakthrough tag
19 Sep 2019 //
REUTERS
Imbruvica scores expanded use in Europe
14 Aug 2019 //
PMLIVE
Imbruvica bags EU expansion for two indications
14 Aug 2019 //
PHARMA TIMES
AZ bags two extensions in latest CHMP decisions
01 Jul 2019 //
PHARMATIMES
FDA lifts hold on AbbVie, Roche`s Venclexta in myeloma
25 Jun 2019 //
FIERCE PHARMA
AstraZeneca`s Calquence sets Imbruvica in its sights
17 Jun 2019 //
FIERCE PHARMA
Roche touts phase 2 Gazyva data in lupus patients
12 Jun 2019 //
FIERCE PHARMA
AstraZeneca`s Calquence treads on Imbruvica`s turf with second phase 3 CLL win
07 Jun 2019 //
FIERCE PHARMA
AbbVie, Roche present positive Venclyxto results at ASCO
06 Jun 2019 //
PHARMATIMES
AbbVie unveils Venclexta data
04 Jun 2019 //
FIERCE PHARMA
Venclexta plus Gazyva approval adds to non-chemo options in CLL
17 May 2019 //
PMLIVE
Roche files Venclexta plus Gazyva in CLL
09 Mar 2019 //
PMLIVE
With 10th FDA OK, Imbruvica further expands in CLL
29 Jan 2019 //
BIOPHARMA DIVE
Imbruvica regimen wins FDA approval 1st non-chemotherapy treatment for leukemia
28 Jan 2019 //
ENDPTS
Imbruvica and Gazyvo approved in first non-chemo CLL use
28 Jan 2019 //
PM LIVE
Genentech to Present New Data from Its Industry-Leading Hematology Portfolio
01 Nov 2018 //
BUSINESSWIRE
AbbVie, Roche combo treatment meets main goal of leukemia trial
01 Nov 2018 //
REUTERS
Four new medicines available via NHS Scotland
12 Sep 2018 //
PHARMA TIMES
Chugai, Nippon Shinyaku bring Gazyva in Japan
31 Aug 2018 //
BIOSPECTRUM
EU Hematology Association Overall Survival Benefit Obinutuzumab Over Rituximab
14 Jun 2018 //
PR NEWSWIRE
AbbVie eyes Imbruvica expansion as Gazyva pairing hits its marks
24 May 2018 //
FIERCE PHARMA
